Enzon Sells Specialty Pharmaceutical Business To Sigma-tau

Published: 27-Jan-2010

Enzon Pharmaceuticals (Enzon) has announced that a special meeting held with its stockholders, has led to the approval for the sale of the company's specialty pharmaceutical business to the Sigma-tau Group.

Enzon's specialty pharmaceutical business includes four marketed products, Oncaspar, Adagen, DepoCyt, and Abelcet, as well as a manufacturing facility in Indianapolis, Indiana.

As previously announced, Enzon entered into a definitive agreement to sell its specialty pharmaceutical business to Sigma-tau for $300m plus, an additional amount of up to $27m based on success milestones.

The company will also receive royalties of 5 to 10% on incremental net sales above a 2009 baseline amount from its four marketed specialty pharmaceutical products through 2014.

The asset sale is expected to be completed later this week.

Enzon Pharmaceuticals is a biopharmaceutical company engaged in the development, manufacturing, commercialization of medicines for patients with cancer and other life-threatening conditions. The company also engages in contract manufacturing for several pharmaceutical companies.

Tell your friend about this article